Abstract
Apart from tight blood glucose control, no other treatments have been shown to retard the progression of diabetic peripheral neuropathy (DPN). Therefore, identifying potential risk factors for DPN is important, particularly if they are modifiable. The Eurodiab baseline DPN study found a prevalence of 28% for DPN, with glycemic control and duration of diabetes being major determinants. It was also observed that a substantial proportion of those with good glucose control (hemoglobin A1c < 7%) were found to have DPN, which raised the possibility that other risk factors may be involved. Having excluded those with DPN at baseline, researchers followed 1172 type 1 diabetic subjects for 7.3 years (SD, 0.6) looking for risk factors for the development of DPN. DPN developed in 23.5% over the follow-up period; and apart from glycemic control and duration of diabetes, known to be important risk factors for DPN, traditional markers of macrovascular disease (eg, hypertension, smoking, obesity, and triglycerides) were found to be independent risk factors. The study was published in the New England Journal of Medicine and suggested that a need exists for clinical trials to confirm if modifying cardiovascular risk factors is an effective treatment for DPN.
Similar content being viewed by others
References and Recommended Reading
Tesfaye S: Advances in the management of painful diabetic neuropathy. Curr Opin Support Palliat Care 2009, 3:136–143.
Vinik AI, Ziegler D: Diabetic cardiovascular autonomic neuropathy. Circulation 2007, 115:387–397.
Boulton AJ, Vinik AI, Arezzo JC, et al.: Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005, 28:956–962.
Quattrini C, Tesfaye S: Understanding the impact of painful diabetic neuropathy. Diabetes Metab Res Rev 2003, 19(Suppl 1):S1–S8.
Forsblom CM, Sane T, Groop PH, et al.: Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998, 41:1253–1262.
Ziegler D: Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care 2008, 31(Suppl 2):S255–S261.
The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group [no authors listed]. Ann Intern Med 1995, 122:561–568.
Shaw JE, Zimmet PZ: The epidemiology of diabetic neuropathy. Diabetes Reviews 1999, 7:245–252.
Forrest KY, Maser RE, Pambianco G, et al.: Hypertension as a risk factor for diabetic neuropathy: a prospective study. Diabetes 1997, 46:665–670.
Young MJ, Boulton AJM, Macleod AF, et al.: A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993, 36:150–154.
Maser RE, Steenkiste AR, Dorman JS, et al.: Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989, 38:1456–1461.
Ziegler D: Diagnosis, staging and epidemiology of diabetic peripheral neuropathy. Diab Nutr Metab 1994, 7:342–348.
Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications study. The EURODIAB IDDM Complications Study Group [no authors listed]. Diabetologia 1994, 37:278–285.
Tesfaye S, Stephens L, Stephenson J, et al.: The prevalence of diabetic neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996, 39:1377–1384.
Tesfaye S, Chaturvedi N, Eaton SEM, et al.: Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352:341–350.
Witte DR, Tesfaye S, Chaturvedi N, et al.: Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia 2005, 48:164–171.
Ziegler D, Rathmann W, Dickhaus T, et al.: Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008, 31:464–469.
Davis TM, Yeap BB, Davis WA, Bruce DG: Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008, 51:562–566.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tesfaye, S., Selvarajah, D. The Eurodiab study: What has this taught us about diabetic peripheral neuropathy?. Curr Diab Rep 9, 432–434 (2009). https://doi.org/10.1007/s11892-009-0070-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11892-009-0070-1